Using Kaiser Permanente healthcare data, researchers compared the rates of annual kidney function decline and ESKD risk in patients with CKD with and without hepatitis C.
With the risk for tenofovir nephrotoxicity in mind, researchers investigated the impact of treatment with sofosbuvir/ledipasvir with or without tenofovir in patients with HCV/HIV coinfection.
The COVID-19 pandemic disrupted all facets of health care. In a recent study, researchers examined how COVID-19-related health care delays have affected the treatment of hepatitis C virus, and how these...
